| 0.0282 -0.013 (-32.05%) | 10-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
RVL Pharmaceuticals plc operates as a specialized pharmaceutical firm, concentrating on the creation and commercialization of medicinal products. These offerings target patient populations with unmet needs within the fields of ocular health and medical aesthetics across the United States, Argentina, and Hungary. Among its key commercialized products is Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution specifically developed for adults experiencing acquired blepharoptosis, or drooping eyelids. The company, whose corporate headquarters are located in Bridgewater, New Jersey, underwent a name change in January 2022, transitioning from its former identity as Osmotica Pharmaceuticals plc.
Sat, 29 Aug 2026
RVL Pharmaceuticals plc (RVLP) Key Financial Ratios – Valuation, Profitability & More - Value Research
Sat, 16 Dec 2023
RVL Pharmaceuticals plc (RVLPQ) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wed, 16 Aug 2023
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.52% - Investing.com
Mon, 10 Apr 2023
RVLP: Bright-Eyed and Bushy-Tailed - Zacks Investment Research
Mon, 03 Apr 2023
RVL Pharmaceuticals Announces that Upneeq® Wins “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty Awards - Yahoo Finance
Sun, 15 Jan 2023
RVL Pharmaceuticals plc (RVLP) Share Price Today | RVL Pharmaceuticals (RVLP) Live NSE/BSE - Value Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|